{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-265612","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2024-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.235469+00:00","generated_at":"2026-05-29T17:43:42.410017+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"KalVista appoints Laurence Reid, Ph.D. to Board of Directors","bullets":["Laurence Reid appointed to KalVista Board effective Nov 23, 2024; term expires at 2027 annual meeting.","Compensation: initial option for 17,000 shares, $42,500 annual cash retainer, annual option for 10,000 shares.","Reid brings over 30 years biotech experience; was CEO of Decibel Therapeutics prior to Regeneron acquisition.","Reid's appointment comes as KalVista progresses sebetralstat toward FDA PDUFA date of June 17, 2025.","Board determined Reid independent under Nasdaq rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-265612","json":"https://secwatch.observer/filing/0001193125-24-265612.json","markdown":"https://secwatch.observer/filing/0001193125-24-265612.md","text":"https://secwatch.observer/filing/0001193125-24-265612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312524265612/0001193125-24-265612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312524265612/d851354d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T17:43:42.410017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}